^
Association details:
Biomarker:MTOR A2034V
Cancer:Breast Cancer
Drug:AZD8055 (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

Excerpt:
Mouse xenografts of MCF-7 cells expressing the RR1 mutant A2034V mTOR showed significantly less sensitivity to rapamycin yet maintained full sensitivity to AZD8055 and RapaLink-1 treatment.